NAPSRx

The U.S. Food and Drug Administration has approved Praluent (alirocumab) Injection to treat high LDL Cholesterol in adult patients.

The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Bristol-Myers Squibb’s investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection...

Exelixis, Inc. has announced positive top line results from METEOR, the pivotal phase 3 trial evaluating COMETRIQ® (cabozantinib) in comparison to everolimus in 658 patients with metastatic renal cell carcinoma (RCC) who have experienced disease...

Otsuka Pharmaceuticals and Lundbeck have received approval from the U.S.

The US Food and Drug Administration (FDA) has officially greenlighted Novartis’ heart failure drug Entresto(TM)  formerly known as LCZ696 to treat heart failure with reduced ejection fraction.

Novartis will acquire Spinifex Pharmaceuticals, a US and Australian-based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain.

According to the “EvaluatePharma World Preview 2015, Outlook to 2020” report, prescription sales are expected to increase 5 percent annually over the next five years across the United States  and Europe.

The U.S. Food And Drug Administration (FDA) has approved Eisai’s antiepileptic agent Fycompa® (perampanel hydrate) to be used as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and...

Allergan plc has agreed to acquire KYTHERA Biopharmaceuticals, Inc for approximately $2.1 billion valued at $75 per KYTHERA share.

In a 13 to 3 vote, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S.